

ANALYSIS OF THE USE OF ORAL ONCOLOGY TARGETED THERAPIES IN A REGION OF SPAIN

Rosas Espinoza C, Alonso Castro V, Maroto García E, García Cerezuela MD, Santos Mena B, Nieves Sedano M, Gómez Caballero EP, Jiménez Moreno P, Alioto D, López Centeno B, Calvo Alcántara MJ

Subdirección General de Farmacia y Productos Sanitarios. Servicio Madrileño de Salud (SERMAS)

BACKGROUND AND IMPORTANCE

Individualised treatments are the most important oncology pharmacotherapeutic innovation nowadays. The high cost of such treatments may hinder their incorporation into clinical practice.






OBJECTIVES

To analyse the impact of the incorporation of oral oncology targeted therapies (OOTT) into routine clinical practice in a region.

MATERIAL AND METHODS

Retrospective, descriptive study of the uptake and economic impact of OOTT between 2012 and 2022. Analysis of incorporation and economic impact included OOTT for six molecular targets, which were dispensed in Hospital Pharmacy Services. ALK/ROS1 mutations were analysed together because the indication of OOTT could not be identified. Regional consumption registers were used as a source of data.



RESULTS



18 authorized drugs at the end of the study

Year 2022 : OOTT treatments had increased by 179% and pharmaceutical expenditure by 494%

The economic impact was 108,138,186€ accumulated over the entire study period



CONCLUSIONS

Targeted therapies have had a relevant impact in recent years, with new drugs and diagnostic techniques increasing the eligible population. Stringent evaluation and adequate selection of these drugs are necessary in order to optimise the incorporation of innovative therapies while guaranteeing the sustainability of the public healthcare system in Spain.

